Calcium Channel Blockers – Benefits Upon Vascular Biology in Hypertensive Patients
| Autor: | Speranta Avram, Daniel Duda-Seiman, Florin Borcan, Livia-Cristina Borcan, Corina Duda-Seiman, Silvia Mancas |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Dihydropyridines Blood Pressure Pulse Wave Analysis Pharmacology Asymptomatic Vascular Stiffness medicine Humans Potency Pulse wave velocity Antihypertensive Agents Aged medicine.diagnostic_test Chemistry Calcium channel Lercanidipine Hematology Middle Aged Cilnidipine Calcium Channel Blockers Blood pressure Hypertension Female medicine.symptom Cardiology and Cardiovascular Medicine Lipid profile medicine.drug |
| Zdroj: | ResearcherID |
| ISSN: | 1871-5257 |
| DOI: | 10.2174/187152571301150730115442 |
| Popis: | Calcium channel blockers (CCB) are widely used in cardiovascular medicine expressing high hopes upon decreasing cardiovascular risk, morbidity and mortality. Here, the potency of CCBs on 58 Romanian asymptomatic hypertensive patients, with no atherothrombotic cardiovascular disease, was studied by clinical and in silico methods. In our study, arterial elasticity/stiffness was assessed; anthropometric, metabolic (lipidic) parameters were quantified. We concluded that lercanidipine 10 mg once daily, during three weeks, is able to dramatically improve central aortic systolic blood pressure, aortic pulse wave velocity. Lipid profile improvement is an essential condition to improve elastic vascular properties in order to decrease the risk for further cardiovascular events. Besides, the potency of lercanidipine is expressed as the contribution of molecular descriptors (van der Waals and solvent accessible surface areas), electronic (molecular polarisability) and hydrophobic (water/octanol partition coefficient) by means of blocker effect on calcium channel, compared with cilnidipine and other 30 dihydropyridines, using molecular simulation techniques. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|